Medical oncologist focused on GU tumors Fundación Jiménez Díaz Hospital
Madrid - Pamplona
Joined September 2011
- Tweets2.1K
- Following286
- Followers315
- Likes2.4K
Imanol Martínez Salas retweeted
Here the 🇧🇪 🇧🇪 Belgium team (Jeremy Blanc & Christof Vulsteke) compare patients stopping or continuing PD(L)1 therapy at 2 yrs in responders (large global retrospective series). The Data suggests it is safe (KM curve green line= stops at 2 yrs; purple line = continues beyond 2 yrs). The recent MIOI randomized trial suggested earlier IO cessation may not be safe, especially in bladder cancer patients. @OncoAlert @DrChoueiri @montypal @PGrivasMDPhD
🇧🇪 The Red Devils are ready to raise some hell at the Uromigos World Cup! ⚽🏆
From the historic streets of Ghent, Team Belgium is tackling a big question in metastatic bladder cancer: When can patients safely stop immunotherapy?
On the pitch and in research, teamwork makes the difference!
#UromigosLive
Imanol Martínez Salas retweeted
TROP2 NMR score paper out on @NatureMedicine
Reminder:
NMR+ = lower ratio of [membrane/(membrane + cytoplasm)] = more TROP2 in the cytoplasm than membrane
Figure 👇 from #WCLC24 presentation was more informative with definitions, IMHO!
nature.com/articles/s41591-0…
Imanol Martínez Salas retweeted
1/9 Our latest manuscript from the #CAPTURE platform in advanced #ProstateCancer is published in @EurUrolOncol. The prognostic impact of BRCA2 gene alterations has been well established, but is BRCA1 comparable to BRCA2? Are all non-BRCA HRR alterations equivalent? 🧵
Imanol Martínez Salas retweeted
EV binds Nectin-4 at the cell surface, so where it’s expressed matters.
In @CCR_AACR, we discuss Klümper et al: a membranous Nectin-4 + NECTIN4 amp score sorts EV ORRs into 77% / 43% / 26%. Next test: EV+pembro. @dsolit @niklas_kluemper @markuseckstein3
🔗doi.org/10.1158/1078-0432.CC…
Imanol Martínez Salas retweeted
🧬 Are we underestimating rare prostate cancer histologies simply because we rarely look for them?
nature.com/articles/s41585-0…
Rare prostate cancer histologies: detection, characteristics and treatment
Rare #ProstateCancer histologies comprise less than 5% of cases but represent a clinically important and under-recognized group.
➡️These subtypes often show aggressive behaviour, atypical metastatic patterns and poorer outcomes, while remaining underrepresented in guidelines and trials.
➡️Accurate diagnosis increasingly depends on multiparametric MRI, immunohistochemistry and genomic profiling.
➡️Molecular alterations such as DNA🧬 repair defects, TP53/RB1 loss and mismatch repair deficiency may offer therapeutic opportunities, highlighting the need for subtype-specific evidence and prospective studies.
@bavilima , @UrogerliMD, @katcollmd, @neerajaiims, @PGrivasMDPhD, @Albert0Briganti, @AndreaNecchi, @LiangChengMD, @SpiessPhilippe
@Oncoalert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Imanol Martínez Salas retweeted
New review: The evolving role of perioperative systemic therapy in #BladderCancer
🔗: acsjournals.onlinelibrary.wi…
@SaadAtiq24 @MattGalsky @TischCancer @IcahnMountSinai @OncoAlert #GUCancer
Imanol Martínez Salas retweeted
📢 #ESMO26 concomitant paper - Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.
🔗shorturl.at/c6tvw
@Daniel_J_George
Imanol Martínez Salas retweeted
Himalayas-1: Rinzimetostat, an Allosteric PRC2 Inhibitor, + Daro: 🌎 Ph 3 RC in mCRPC Previously Treated with Abiraterone @urotoday #ESMO26 @quimmateo
📌n=600
📌1:1 to rinzimetostat + Daro vs physician’s choice of ARPI or docetaxel
📌Prim EP: rPFS
📌Sec EP: OS
Imanol Martínez Salas retweeted
ESMO 2026 - presidential LBA | VOLGA Phase III –
Perioperative Durvalumab + Enfortumab Vedotin (EV) in cisplatin-ineligible/refusing patients:
📊 EV + Durva vs Control
• 2-year EFS: 64% vs 45% (HR 0.51; p<0.0001)
• 2-year OS: 78% vs 69% (HR 0.58; p=0.0027)
• pCR: 45% vs 10%
Adding tremelimumab improved EFS (HR 0.61) but no significant OS benefit yet, with higher grade 3/4 toxicity (42% vs 30%).
🔥can this stop the need of post op EV ? Probably yes . New SOC 🙂👍
Looking forward the full datasets @OncBrothers
@OncoAlert @myESMO
#ESMO26 #VOLGA #BladderCancer
Imanol Martínez Salas retweeted
Daro + ADT and docetaxel in mHSPC: RW Evidence from the TRIDA Study of SOGUG 🇪🇸 #ESMO26 @urotoday @Ricardo62949193
mFU: 11 mos
📌16.2% progressed to CRPC
📌mOS NR, 18 mo probability of survival: 86.5%
📌48.5% PSA <= 0.2
📌83.3% disease control
📌Similar safety to ARASENS
Imanol Martínez Salas retweeted
🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯
#BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866
#ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS
#KidneyCancer: LITESPARK-011 & -012, ivonescimab, PE-PE, SWOG S2200, XmAb819
Our Participating Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger , @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi , @AmandaNizamMD, @drenriquegrande, @nataliagandur
@AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun , @ravikanesvaran , @BraunMDPhD, @EfstathiouEleni, @mzugman , @crisbergerot, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas , @sonpavde , @Dr_Oncologista
Imanol Martínez Salas retweeted
Worth reading: a sharp analysis of PROTEUS trial results by @DrSpratticus 👇
nature.com/articles/s41571-0…
Imanol Martínez Salas retweeted
🚨 In advanced #ProstateCancer, BRCA status correlates with response to AR-directed therapy 🚨
@CRC_AACR @AACR, pooled analysis of 5 randomized ARPI trials (apalutamide or abiraterone):
👥 608 pts on ARPI-based regimens, HRR status by tissue or plasma sequencing
📊 Retrospective pooled biomarker analysis, endpoints rPFS and OS
✅ BRCA-altered pts did worse on ARPIs:
Progression HR 1.8 (1.16-2.79) p=0.009,
Mortality HR 1.6 (1.02-2.34) p=0.038
✅ HRR-altered (any) had shorter
rPFS, HR 1.7 (1.2-2.3), p=0.001
✅ HRR-altered men still benefit from intensifying: adding ARPI to ADT prolonged:
rPFS HR 0.42 (0.2-0.89)
OS HR 0.45 (0.23-0.91)
⚠️ Retrospective, ARPIs limited to Apa/Abi. Hypothesis-generating for combinations
🎯 HRR and especially BRCA alterations = aggressive biology, still, they benefit from ARPi benefits
🔗 doi.org/10.1158/2767-9764.CR…
@UroOnc @PCFnews @PCF_Science @SUO_YUO @UrologyTimes @urotoday
Imanol Martínez Salas retweeted
More evidence for Nectin4 as a biomarker for EV in @EUplatinum
In 1L EV+P, high Nectin4 RNA expression was associated with ⬆️ORR and OS but this was not seen with Pembro alone.
Data on membranous expression & amplification might be useful.
@OncoAlert
europeanurology.com/article/…
Imanol Martínez Salas retweeted
How does bladder cancer spread? 🔬 New work published today in @Nature uses clonal tracing to show that new metastases are predominantly seeded by an earlier metastasis, potentially highlighting a critical window for intervention with metastasis-directed therapies. @fredhutch
Ever wonder how heterogeneity defines bladder cancer subtypes?
Ha and Hsieh Lab postdoctoral fellows @pushpa_itagi and Samantha Schuster @fredhutch did, leading to a deep study of bladder cancer clonality, evolution, and heterogeneity published @Nature
nature.com/articles/s41586-0…
Imanol Martínez Salas retweeted
Could NECTIN4 localization—and not just expression—help us identify which patients are most likely to benefit from enfortumab vedotin?
Article 📰
buff.ly/ZoHD2ie
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma
In this retrospective analysis of 179 EV-treated patients with metastatic urothelial carcinoma, high membranous NECTIN4 🧬 expression predicted response, PFS, and OS, whereas cytoplasmic expression did not. NECTIN4 amplification identified a particularly favorable subgroup.
➡️ An integrated model combining amplification and membranous expression further stratified response and survival, suggesting a potential biomarker framework for optimizing EV selection. #BladderCancer
@niklas_kluemper, @piapiacere, @Richard_Weiten, @susanne_fussel, @jcasusce, @KuppeChristoph, @JoshMeeks, @bonnie_choy, @braegelmannlab, @HolzelMichael, @ViktorGruenwald, @Markuseckstein3
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @AlbigesL, @cdanicas, @amerseburger, @sonpavde, @DrDanielHeng, @declangmurphy, @seanmmcbride, @HHammersMD, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @scocmem, @AmandaNizamMD, @drenriquegrande, @BraunMDPhD, @EfstathiouEleni, @nataliagandur, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD
Imanol Martínez Salas retweeted
🚨 8 mutational processes explain 85% of primary #prostatecancer genomes 🚨
@Nature, Pan Prostate Cancer Group:
👥 959 primary tumours w/ WGS, median f/u 7 yrs
📊 SBS + indel + copy number + 6 new complex SV signatures combined into 8 integrated footprints
✅ 4 of them, in 37% of tumours, predicted metastasis independent of age, Gleason, stage, TMB (HRs 4.05 to 7.71)
✅ The same signatures analyzed one at a time predicted nothing, need to know the dominant cluster!
✅ In mCRPC, a replication-stress footprint predicted ARPI over taxane: HR 0.21 for treatment failure
⚠️ Retrospective, ARPI signal rests on 25 pts, WGS of course not routine practice
🎯 Bottom line: we keep asking is it HRD, is it BRCA. Under 3% of primary PCa answer yes. Integrate four kinds of variation instead and you stratify 85% of genomes.
🔗 doi.org/10.1038/s41586-026-1…
@AmerUrological @UroOnc @PCFnews @PCF_Science @SUO_YUO @UroOnc
Imanol Martínez Salas retweeted
⚡️ Real-world quality of life outcomes in metastatic urothelial cancer treated with EV + pembrolizumab: QoL improved in responders, but deteriorated in patients who progressed.
Efficacy and patient-reported outcomes tell different stories — both matter for shared decision-making.
ascopubs.org/doi/10.1200/OA-…
@AndreaNecchi @JCO_ASCO
#BladderCancer
